Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality. Since sleep ...

Eli Lilly's Zepbound outperformed Novo Nordisk's top weight loss drug in a recent study. Both drugs showed that they were highly effective in helping people lose weight, but Zepbound's numbers ...

Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have been barriers to more widespread use by patients. Eli Lilly headquarters ...

Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years. Which of these companies will ...

Eli Lilly's weight loss drug, Zepbound, was recently involved in a head-to-head trial against Wegovy, and the results indicated that the former is the clear winner in helping people lose weight.